Evidence map›Paper›PMID 39718616›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Combined Ribociclib and NU7026 administration enhances radio-sensitivity by inhibiting DNA repair in prostate cancer.

Jinbo Sun, Yong Wang, Shanjin Ma, Wei Zhang, Longfei Yang, Bo Zhang, Qisheng Tang

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Jinbo Sun *Department of Urology, General Hospital of the Central Theater Command, Wuhan, 430070, Hubei, China.
Yong Wang *Department of Urology, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Xi'an, 710038, Shaanxi, China.
Shanjin Ma *Department of Urology, the 955th Hospital of Army, Changdu, 854000, Tibet, China.
Wei ZhangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Xi'an, 710038, Shaanxi, China.
Longfei YangDepartment of Medical Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, Shaanxi, China.
Bo ZhangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Xi'an, 710038, Shaanxi, China. zhangbotd2020@126.com.ORCID 0009-0001-2729-100X
Qisheng TangDepartment of Urology, Tangdu Hospital, Fourth Military Medical University, No.569 Xinsi Road, Xi'an, 710038, Shaanxi, China. tanglefoot@163.com.ORCID 0000-0001-9280-0088

Funding

National Natural Science Foundation of China 81672535Talent Cultivating Project of General Hospital of the Central Theater Command ZZYCZ202101
6 · The paper itself

Abstract

Radiosensitivity is critical for clinical outcomes and overall survival of prostate cancer patients treated with irradiation. Ribociclib and NU7026 have been reported as radiosensitizers in cancer cells, but which are inadequately understood in prostate cancer cells. The present study was performed to investigate the effects of ribociclib, NU7026, and their combination on the radiosensitivity of prostate cancer cells. Optimal combined concentrations of ribociclib and NU7026 with X-irradiation were selected. Flow cytometry, CCK-8 assays, soft agar colony formation, and γH2AX foci formation assays were performed to assess the cell cycle distribution, cell viability, cell proliferation, and DNA damage, respectively. Finally, the expression of proteins related to the cell cycle, DNA repair, and cell death was evaluated by western blot analysis. Ribociclib arrested prostate cell cycle in the G0/G1 phase. Compared with the control, X-irradiation combined with ribociclib or NU7026 significantly decreased cell proliferation, reduced colony formation, and enhanced γH2AX foci formation in PC3 and DU145 cells. Moreover, the protein expression levels of CDK4, p-Rb, cyclin D1, rad51, and DNA-PKcs were significantly decreased, whereas that of Bax was significantly increased.The combination of ribociclib and NU7026 may be a potential strategy for prostate cancer therapy by promoting radiosensitivity.

Indexed as

AminopyridinesChromonesDNA RepairMorpholinesProstatic NeoplasmsPurinesRadiation-Sensitizing AgentsRadiation ToleranceCell CycleCell Line, TumorCell ProliferationCell SurvivalHumansMale8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-oneAminopyridinesChromonesMorpholinesPurinesRadiation-Sensitizing AgentsribociclibCell cycleDNA repairNU7026Prostate cancerRadio-sensitivityRibociclib

Identifiers

PMID39718616

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.